Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.43 |
| ▸ | SGK1 | O00141 | 1/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.42 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213163 | 0.84 | NAPRT (0.67) | NAPRTSMN1; SMN2MAPTKCNQ3KCNQ2 | |
| SCHEMBL29592337 | 0.84 | NAPRT (0.67) | NAPRTSMN1; SMN2MAPTKCNQ3KCNQ2 | |
| SCHEMBL1109095 | 0.83 | NAPRT (0.71) | NAPRTKCNQ3KCNQ2PIK3CDCYP2A6 | |
| SCHEMBL27417480 | 0.82 | NAPRT (0.50) | NAPRTSMN1; SMN2MAPTKCNQ3KCNQ2 | |
| SCHEMBL5075261 | 0.81 | MKNK1 (0.66) | NAPRTKCNQ3KCNQ2PIK3CDMKNK1 | |
| SCHEMBL24198706 | 0.81 | NAPRT (0.49) | NAPRTSMN1; SMN2KCNQ3KCNQ2PIK3CD | |
| SCHEMBL38659193 | 0.81 | KDM4E (0.50) | NAPRTSMN1; SMN2MAPTKCNQ3KCNQ2 | |
| SCHEMBL22575128 | 0.81 | CSNK2A1 (0.52) | NAPRTSMN1; SMN2KCNQ3KCNQ2PIK3CD | |
| SCHEMBL2952147 | 0.81 | KDM4E (0.50) | NAPRTSMN1; SMN2MAPTKCNQ3KCNQ2 | |
| SCHEMBL27417479 | 0.81 | MAPT (0.56) | NAPRTSMN1; SMN2MAPTKCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486246-B2 | Replication protein A (RPA)-DNA interaction inhibitors | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-12-02 | — | — | US | disclosed |
| US-20230056729-A1 | REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-02-23 | — | — | US | disclosed |
| EP-4073055-A1 | REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS | The Trustees of Indiana University (US) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021119242-A1 | REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2021-06-17 | — | — | WO | disclosed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2233470-A1 | Histamine H3 receptor antagonists | High Point Pharmaceuticals, LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| CN-101218206-A | Histamine H3 receptor antagonists | NOVO NORDISK AS (DK) | 2008-07-09 | — | — | CN | disclosed |
| EP-1902028-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS | Novo Nordisk A/S (DK) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232078-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | NAPRT 2037/4885SMN1; SMN2 3870/4885HSD17B1 3783/4885 |
| US-20090312309-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | NAPRT 2037/4885SMN1; SMN2 3870/4885HSD17B1 3783/4885 |
| US-12486246-B2 | Replication protein A (RPA)-DNA interaction inhibitors | RPA1, RPA3, RPAP1 | NAPRT 931/4885SMN1; SMN2 4309/4885HSD17B1 3780/4885 |
| US-20230056729-A1 | REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS | RPA1, RPA3, RPAP1 | NAPRT 931/4885SMN1; SMN2 4309/4885HSD17B1 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.